Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated

[1]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[2]  J. Douketis,et al.  Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[3]  A. Iorio,et al.  Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.

[4]  J. Douketis,et al.  Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism , 2010, Annals of Internal Medicine.

[5]  A. Iorio,et al.  Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting , 2010, Journal of thrombosis and haemostasis : JTH.

[6]  Georg Heinze,et al.  Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.

[7]  A. Tosetto,et al.  Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study , 2010, Thrombosis and Haemostasis.

[8]  A. Iorio,et al.  Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. , 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[9]  Stacy A. Johnson,et al.  Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. , 2010, JAMA.

[10]  A. Tosetto,et al.  Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. , 2010, Blood.

[11]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[12]  W. Ageno,et al.  Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis: A Randomized Trial , 2009 .

[13]  J. Douketis,et al.  Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism , 2008, Annals of Internal Medicine.

[14]  S. Kahn,et al.  Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy , 2008, Canadian Medical Association Journal.

[15]  G. Mariani,et al.  Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. , 2008, Blood.

[16]  R. Beyth,et al.  Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[17]  G. Raskob,et al.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[18]  H. Büller,et al.  Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. , 2008, Blood.

[19]  C. Kearon,et al.  Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  D. P. Bentley,et al.  Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial , 2007, BMJ : British Medical Journal.

[21]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. , 2007, Haematologica.

[22]  A. Iorio,et al.  D-dimer testing to determine the duration of anticoagulation therapy. , 2006, The New England journal of medicine.

[23]  S. Schulman,et al.  Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis , 2006, The Lancet.

[24]  O. Linder,et al.  Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months , 2006, Journal of thrombosis and haemostasis : JTH.

[25]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[26]  B. Cosmi,et al.  D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis , 2005, Thrombosis and Haemostasis.

[27]  Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. , 2004, Thrombosis and haemostasis.

[28]  R. Farraj.  Anticoagulation period in idiopathic venous thromboembolism. How long is enough? , 2004, Saudi medical journal.

[29]  J. Douketis,et al.  Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor , 2004, Journal of thrombosis and haemostasis : JTH.

[30]  M. Gent,et al.  Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism , 2004 .

[31]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[32]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[33]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[34]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[35]  C. Kearon,et al.  Natural History of Venous Thromboembolism , 2003, Circulation.

[36]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[37]  M. Prins,et al.  Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism , 2002, Annals of Internal Medicine.

[38]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[39]  P. Romano,et al.  Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.

[40]  B. Cosmi,et al.  Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped , 2002, Thrombosis and Haemostasis.

[41]  L. Galli,et al.  Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. , 2002, Haematologica.

[42]  W. Ageno,et al.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.

[43]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[44]  J. Hirsh,et al.  A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy , 2000, Thrombosis and Haemostasis.

[45]  Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta‐analysis of randomized, controlled trials , 2000, Journal of internal medicine.

[46]  H. Eriksson,et al.  Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.

[47]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[48]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[49]  L. Melton,et al.  Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.

[50]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[51]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[52]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[53]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.